TVA Medical - search results
If you're not happy with the results, please do another search
BD acquires TVA Medical, makers of everlinQ endoAVF System
BD (Becton, Dickinson and Company) announced it has completed the acquisition of TVA Medical, a company that develops minimally invasive vascular access solutions...
BD acquires TVA Medical, makers of everlinQ endoAVF System
BD (Becton, Dickinson and Company) announced it has completed the acquisition of TVA Medical, a company that develops minimally invasive vascular access solutions...
TVA Medical receives CE mark for everlinQ 4 endovascular AVF system
TVA Medical’s everlinQ 4 endovascular arteriovenous fistula (AVF) system has received CE mark in the European Union. The technology uses a 4F catheter system...
TVA Medical presents positive everlinQ endoAVF system results at LINC 2017
TVA Medical has provided clinical updates involving its everlinQ endoAVF system at the 2017 Leipzig Interventional Course (LINC; 24-17 January, Leipzig, Germany).
Scientific data regarding the...
TVA Medical receives additional reimbursement in Germany for everlinQ endoAVF system
TVA Medical's everlinQ endoAVF system has received NUB (German Neue Untersuchungs und Behandlungsmethoden) Status 1 approval across more than 80 leading hospitals in Germany.
TVA Medical wins innovation award for minimally invasive haemodialysis access system
The company received the honour for its everlinQ System, a catheter-based technology designed to create haemodialysis access for chronic kidney disease patients in a minimally-invasive procedure.
everlinQ endoAVF receives FDA de novo marketing approval
everlinQ endoAVF System (TVA Medical) is now approved by the US Food and Drug Administration for de novo marketing. This innovative, minimally invasive technology...
New data on quality of life and cost savings for everlinQ endoAVF System
A recent healthcare analysis shows that a novel, catheter-based endovascular system for creating haemodialysis access offers quality-of-life benefits and cost savings compared to the...
Meta-analysis shows positive experience for endoAVF patients for haemodialysis access
An international meta-analysis of clinical experience in patients who received an endovascular arteriovenous fistula (endoAVF) for haemodialysis access was presented at Leipzig Interventional Course...
Twelve-month NEAT trial data promising for everlinQ endoAVF haemodialysis access system
TVA Medical has announced the online publication of positive results from the Novel Endovascular Access Trial (NEAT) evaluating its everlinQ endoAVF system. The 12-month...
NEAT trial shows six times fewer post-creation interventions with endovascular than with traditional surgical...
NEAT (Novel endovascular access trial) data presented at the Vascular Interventional Advances (VIVA) 2016 meeting (18–22 September, Las Vegas, USA) suggest that endovascular arteriovenous...
Primary endpoint data from NEAT study announced at Leipzig Interventional Course 2016
Primary endpoint data from a prospective, multicentre clinical study evaluating the everlinQ endoAVF system have been announced by TVA Medical. The system is designed to...
New technologies for arteriovenous fistula: the future is bright and the future is now
Since the adoption of the “fistula first” initiative, greater attention has been given to creation and maintenance of arteriovenous vascular accesses, especially arteriovenous fistulae....
everlinQ system shows 98% success in creating endovascular arteriovenous fistulae
TVA Medical has announced clinical trial results from a prospective, multicentre clinical study evaluating the everlinQ endovascular arteriovenous fistula system. This medical technology creates haemodialysis...
New everlinQ vascular access system demonstrates positive outcomes in dialysis patients
Results from a clinical study evaluating the novel haemodialysis access technique for patients with chronic kidney disease were published online in the Journal of Vascular and Interventional Radiology.
PRELUDE-BTK subanalysis highlights superior lumen gain, greater volumetric blood flow using serration angioplasty
Cagent Vascular has announced the results of a comparative subanalysis of the PRELUDE-below-the-knee (BTK) study versus plain balloon angioplasty.
The study was led by Marianne...
“Starting to close the door on the paclitaxel controversy”: Late-breaking trials presented at TCT...
Findings from a series of late-breaking trials in the endovascular field were presented recently at TCT Connect (14–18 October, virtual), the 32nd annual scientific...
Cagent Vascular appoints Brian Walsh as chairman of the board
Cagent Vascular, a developer of next-generation angioplasty balloons using proprietary serration technology, announces Brian Walsh to serve as chairman of the Board.
Brian Walsh...
Abbott initiates trial for peripheral stent system
Abbott announces the initiation a clinical trial of the Absolute Pro peripheral self-expanding stent system in patients with iliac artery disease
